Ozempic Safety News

Latest News on Ozempic

FDA Finds No Link Between Ozempic, Wegovy, and Suicide Risk In a significant development, the Food and Drug Administration (FDA) has concluded that there is no clear evidence linking GLP-1 weight-loss drugs like semaglutide, marketed as Ozempic and Wegovy, to suicidal thoughts or actions. This comes as a relief amid previous concerns about the mental health effects of these medications. The FDA's preliminary review indicates that these drugs may even pose a lower risk of suicidal ideations compared to other treatments for diabetes and obesity. While the FDA continues its investigation, the early findings are promising. A new weight-loss drug, potentially surpassing the effectiveness of Wegovy and Ozempic, is anticipated in 2024. Read more.

Studies Reassure on Mental Health Effects of Ozempic and Wegovy Further studies have reinforced the FDA's findings, showing little evidence of negative mental health impacts from popular diabetes and weight loss drugs, including Ozempic and Wegovy. This news comes as a positive sign for users of these medications, as earlier reports had raised concerns about a possible link to suicidal thoughts. The ongoing FDA reviews and new research collectively suggest a safe profile for these widely-used GLP-1 drugs. Read more.

These updates highlight a significant milestone in the understanding of the safety profile of Ozempic and Wegovy, providing reassurance to millions relying on these medications for managing diabetes and weight loss.